Vanderbilt University

Thallion Pharmaceuticals Inc.

Ecopia Biosciences, Inc.

James B. Mc Alpine

Emmanuel Zazopoulos

Chris M. Farnet

Brian O. Bachmann

Brian O Bachmann

Chris M Farnet

James B McAlpine

Kasia Derewacz

Emilianne M Limbrick

Darryl J Bornhop

Mahmood Piraee

Violetta Dimitriadou

Nargis Ismail

Stephen Dotson

James B Mcalpine

Disclosed are methods of preparing everninomicin analogs by genetic alteration of. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclose.

Biosynthesis of everninomicin analogs invar

Disclosed are methods of preparing everninomicin analogs by genetic alteration of. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclosed.

A polarimetry technique for measuring optical activity that is particularly suited for high throughput screening employs a chip or substrate () having one or more microfluidic channels () formed therein. A polarized laser beam () is directed onto optically active samples that are disposed in the channels. The incident laser beam interacts with the optically active molecules in the sample, which slightly alter the polarization of the laser beam as it passes multiple times through the sample. Interference fringe patterns () are generated by the interaction of the laser beam with the sample and the channel walls. A photodetector () is positioned to receive the interference fringe patterns and generate an output signal that is input to a computer or other analyzer () for analyzing the signal and determining the rotation of plane polarized light by optically active material in the channel from polarization rotation calculations.

On-chip polarimetry for high-throughput screening of nanoliter and smaller sample volumes

This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains of; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains ofused to produce these compounds, to the use of these compounds and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. The invention also relates to pharmaceutical compositions comprising these novel polyketides or a pharmaceutically acceptable salts or derivatives thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides.

Polyene polyketides, processes for their production and their use as a pharmaceutical

Polyene oxazoles of the following formula wherein Ris selected from H and methyl, are disclosed. Such compounds, and pharmaceutically acceptable salts thereof, may be used in the inhibition of tumor cell growth. The polyene oxazoles and their pharmaceutically acceptable salts may be formulated as pharmaceutical compositions with pharmaceutically acceptable carriers for use in the inhibition of tumor cells. The polyene oxazoles may be obtained from strains of, such as strain 022 having deposit number IDAC 270504-04.

Polyene oxazoles and processes for their preparation

This invention relates to methods of inhibiting growth of a cancer cell and methods of treating cancer using a novel farnesylated dibenzodiazepinone.

Farnesyl dibenzodiazepinones and methods of treating cancer using same

This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain ofsp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates tosp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

Growing community of inventors

Nashville, TN, United States of America

Brian O Bachmann